STOCK TITAN

electroCore to Participate at Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

electroCore, Inc. (Nasdaq: ECOR) announced that CEO Dan Goldberger will hold one-on-one meetings at the Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum on November 17, 2022. electroCore focuses on bioelectronic medicine, aiming to enhance patient outcomes through non-invasive vagus nerve stimulation therapy. Their current treatments address several neurological conditions, including cluster headaches and migraines.

Loading...
Loading translation...
Argus Session date unavailable
+22.78% session move Open Argus
Details

News Market Reaction – ECOR

The recorded move for ECOR in the trading session of this news was +22.78%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

ROCKAWAY, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger, will be conducting one-on-ones at the Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum.

Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum
Date:  Thursday, November 17, 2022
Event: One-on-one meetings

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit www.electrocore.com.

Investors:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the date of the Canaccord Genuity Forum for electroCore?

The Canaccord Genuity Forum for electroCore is scheduled for November 17, 2022.

Who will represent electroCore at the Canaccord Genuity Forum?

Dan Goldberger, the CEO of electroCore, will represent the company at the forum.

What conditions does electroCore's therapy focus on?

electroCore's therapy focuses on treating cluster headaches and migraines, among other neurological conditions.

What is electroCore's stock symbol?

The stock symbol for electroCore is ECOR.

Where can I find more information about electroCore?

More information about electroCore can be found on their website at www.electrocore.com.

Keep reading